Sign in
SR

Sila Realty Trust, Inc. (SILA)·Q4 2024 Earnings Summary

Executive Summary

  • Q4 delivered steady operating results: revenue rose to $46.5M (vs. $45.9M YoY; $46.1M QoQ), diluted EPS was $0.20 (vs. $(0.16) YoY; $0.21 QoQ), Cash NOI was $41.0M (vs. $42.8M YoY), and AFFO was $30.2M or $0.54/sh (vs. $32.7M YoY; $31.7M QoQ) .
  • Portfolio quality and duration improved: leased rate ticked up to 96.0% (from 95.5% in Q3) and WALT extended to 9.7 years, driven by 15 Post Acute Medical lease extensions and resolution of remaining GenesisCare assets .
  • Balance sheet/liquidity remained strong and improved further post quarter: $539.8M liquidity at year-end; revolver upsized to $600M on Feb 18, 2025; net debt/EBITDAre 3.3x, with a long-term target of 4.5x–5.5x providing capacity for external growth .
  • No formal 2025 guidance; management targets 7.5%–15% enterprise growth with an acquisition-heavy mix; catalysts include lease-up/sale of Stoughton, additional accretive acquisitions, and benefits from mezzanine development financing .

What Went Well and What Went Wrong

  • What Went Well

    • Lease duration/tenant health improved: 20-year extensions across 15 Post Acute Medical leases increased WALT to 9.7 years; overall portfolio EBITDARM improved to 5.3x with <2% of ABR below 1.0x coverage .
    • Capital availability: new $600M revolver (oversubscribed), enabling external growth in a “higher-for-longer” rate environment .
    • Portfolio optimization: final two GenesisCare properties resolved (one sold, one re-leased to investment-grade UC Regents) and occupancy edged up to 96.0% .

  • What Went Wrong

    • Cash NOI and AFFO declined YoY on dispositions > acquisitions, GenesisCare lease changes, Steward vacancy, and selective resets to market in exchange for term; Q4 Cash NOI $41.0M (vs. $42.8M YoY) and AFFO $30.2M (vs. $32.7M YoY) .
    • Interest hedge resets increased swap rates (0.93% → 3.76%) as five swaps matured 12/31/24, creating a headwind to run-rate interest expense .
    • Stoughton (Steward) remains a drag pending sale/lease; carry costs persist until disposition or re-tenanting is completed .

Financial Results

MetricQ4 2023Q3 2024Q4 2024
Revenue ($USD Millions)$45.914 $46.118 $46.545
Net Income ($USD Millions)$(8.996) $11.935 $11.114
Diluted EPS ($)$(0.16) $0.21 $0.20
Cash NOI ($USD Millions)$42.803 $40.812 $40.960
AFFO ($USD Millions)$32.697 $31.714 $30.235
AFFO per Share - Diluted ($)$0.57 $0.57 $0.54
EBITDAre ($USD Millions)$33.560 $36.060 $33.859

Portfolio and balance sheet KPIs

KPIQ2 2024Q3 2024Q4 2024
Weighted Avg Leased Rate97.5% 95.5% 96.0%
Weighted Avg Remaining Lease Term (years)8.2 8.3 9.7
Number of Properties137 136 135
Liquidity ($USD Millions)$586.971 $528.606 $539.844
Net Debt / EBITDAre (x)3.1x 3.5x 3.3x

Notes and drivers

  • Q4 diluted EPS rose sharply YoY on absence of prior-year impairment/disposition losses and lower interest expense vs. 2023, despite Cash NOI/AFFO pressure from asset churn and lease resets .
  • Cash NOI margin fell YoY (88.0% vs. 93.2%) as redeployment timing and specific tenant events outweighed rent escalators; Q3 margin was 88.5% .

Guidance Changes

MetricPeriodPrevious Guidance/StatusCurrent UpdateChange
Distribution Frequency2025Monthly distributionsShift to quarterly distributions effective 2025Maintained payout cadence; frequency changed
Quarterly Dividend/ShareQ1 2025N/A (monthly $0.1333 during 2024)Declared $0.40 payable Mar 26, 2025Maintained $1.60 annualized run-rate
Revolving Credit Facility CapacityAs of 12/31/24 vs. 2/18/25$500M availability at 12/31/24Upsized to $600M on Feb 18, 2025Raised capacity
Leverage Target (Net debt/EBITDAre)2025 frameworkModerate leverage; ~4.5x–5.5x target historically indicatedReiterated 4.5x–5.5x long-term targetMaintained
2025 Formal Financial Guidance (AFFO/EPS/Revenue)FY 2025Not providedNot providedUnchanged (no formal guide)

Earnings Call Themes & Trends

TopicPrevious Mentions (Q2 2024 and Q3 2024)Current Period (Q4 2024)Trend
Tenant health/coverageReporting ABR coverage 4.64x (Q2); 4.82x (Q3). GenesisCare/Steward issues weighed on NOI .Coverage improved to 5.3x; <2% ABR below 1.0x; three tenants at two properties below 1.0x, all current on rent .Improving credit metrics
Portfolio occupancy/WALTLeased 97.5% (Q2) and 95.5% (Q3); WALT 8.2–8.3 years .Leased 96.0%; WALT extended to 9.7 years via 20-year PAM extensions; GenesisCare resolved .Duration/occupancy stabilizing upward
Capital markets/liquidityNYSE listing; $500M availability; tender offer completed .$539.8M liquidity at YE; revolver upsized to $600M in Feb 2025 (oversubscribed) .Greater funding capacity
Development/mezz strategyMezz opportunities noted (Q3 disclosed post-quarter) .Executed two mezz loans (IRF/behavioral) with options to acquire; mid-teens returns during funded period .New growth vector building pipeline
Dispositions/problem assetsFort Myers sold; GenesisCare assets being sold/leased; Stoughton under contract (later terminated) .Yucca Valley sold; El Segundo re-leased to UC Regents; Stoughton actively marketed by national broker .Legacy headwinds easing; one asset remains
Macro/rates“Higher for longer” emerging in H2; swaps resetting in late 2024 .Rates seen as new normal; swaps reset to 3.76% on $250M notional; cap rates 6.5–7.5% range targeted .Realistic return hurdles and pricing discipline

Management Commentary

  • CEO (press release): “We realized a meaningful increase to our portfolio ... eight properties for approximately $164.1 million... closed on two mezzanine loans totaling $17.5 million... expected to provide... strong risk adjusted returns... creating future pipeline opportunities with purchase options” .
  • CEO (call): “Our forward-footed positioning starts with the recent recast of our revolving line of credit... oversubscribed by 70%... demonstrate confidence... while others sit on the sidelines” .
  • CIO (call): “We executed renewal leases and lease modifications for in excess of 1.1 million rentable square feet... in Q4, we renewed all 15 leases with our largest tenant, Post Acute Medical, extending... to 20 years with no change to base rent” .
  • CFO (call): “AFFO was $30.2 million, or $0.54 per diluted share... driven by timing of net investment activity... amended master lease with GenesisCare, [and] the closure of the former Steward property... Q4 AFFO had no material one-time items” .

Q&A Highlights

  • No formal 2025 guide; modeling context: management aims to grow enterprise 7.5%–15% via disciplined, accretive acquisitions; mezz loans to be a smaller mix vs. fee-simple acquisitions .
  • Capital structure: new $600M revolver enables levering to 4.5x–5.5x net debt/EBITDAre through accretive deals; YE24 at 3.3x .
  • Tenant health: only three tenants at two properties below 1.0x coverage and all current; broad improvement vs. last quarter .
  • Stoughton (Steward): actively marketed for sale/lease; management agnostic to outcome but highlights meaningful carry costs that would end on sale .
  • Acquisition market: increased off-market deal flow; focus on MOBs, IRFs, specialty surgical/micro-hospitals in “Smile States”; cap rates typically 6.5%–7.5% .

Estimates Context

  • Wall Street consensus estimates (S&P Global) for Q4 2024 EPS and revenue were unavailable at the time of this analysis; therefore, no beat/miss determination is provided. The company did not issue formal 2025 guidance on the call .
  • Where estimates are required for portfolio models, users should update with S&P Global consensus once available.

Key Takeaways for Investors

  • Defensive cash flows with improving tenant metrics and extended WALT to 9.7 years reduce near-term leasing risk and support durable AFFO, even amid rate headwinds .
  • External growth optionality is high: $600M revolver, moderate leverage (3.3x ND/EBITDAre YE), and index inclusion momentum should support capital access and pipeline execution .
  • Earnings cadence is temporarily damped by prior dispositions, GenesisCare restructuring, and swap resets; YoY Cash NOI/AFFO softness reflects mix and timing, not core deterioration .
  • Mezzanine development loans add mid-teens return opportunities and embedded purchase options, enhancing future accretive acquisition pipeline .
  • Resolution of the remaining Steward/Stoughton asset is a near-term catalyst to remove drag and potentially boost occupancy .
  • Dividend maintained at $1.60 annualized with a 73% AFFO payout in Q4, supported by net-lease structure and rent escalators .
  • Watch for 2025 deal flow skewed to fee-simple acquisitions; management is disciplined on cap rate/credit/term and sees better off-market opportunities as peers remain constrained .

Supporting Details and Additional Data

Q4 2024 non-GAAP detail and YoY bridge

  • AFFO $30.2M ($0.54/sh) vs. $32.7M YoY; primary drivers: disposition > acquisition NOI, GenesisCare lease amendments, Steward bankruptcy-related vacancy; partly offset by rent escalators and selective one-time items earlier in the year (GenesisCare payment) .
  • Cash NOI $41.0M vs. $42.8M YoY; Cash NOI margin 88.0% vs. 93.2% YoY .

Dividend and payout

  • Declared $0.40/share quarterly dividend payable Mar 26, 2025 (annualized $1.60); Q4 payout to AFFO 73.3% .

Liquidity and swaps

  • YE liquidity $539.8M ($39.8M cash + $500M undrawn revolver) .
  • Four new swaps effective 12/31/24 at 3.76% (aggregate $250M notional) replaced five maturing swaps at 0.93% (reset headwind) .

Real estate activity

  • 2024 acquisitions: 8 properties, $164.1M; Q4 sold Yucca Valley ($1.7M) and re-leased El Segundo to UC Regents (10-year term) .
  • Mezz loans: $17.5M total commitments (IRF and behavioral hospital) with purchase options; unfunded commitments $17.5M at YE .

Conference call access (archived)

  • Feb 26, 2025 earnings call webcast details in the release .